Lixte Biotechnology (LIXT) Stock Price, News & Analysis

Company Overview

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms. These candidates are currently advancing through early-phase clinical trials in solid tumors, where Lixte is evaluating safety, tolerability and preliminary measures of anti-tumor activity. Research and development activities are conducted in collaboration with academic institutions and contract research organizations to leverage cutting-edge science and streamline the path to clinic.

Headquartered in the United States, Lixte Biotechnology maintains its R&D operations in California and works with strategic partners to extend its global reach. The company’s leadership team comprises seasoned executives and scientists with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Through disciplined pipeline management and targeted clinical development, Lixte aims to deliver differentiated therapies that address significant unmet needs in cancer care.

Key Stats

• Today's Range: $7.00 to $7.99
• 50-Day Range: $6.19 to $8.04
• 52-Week Range: $2.02 to $8.38
• Volume: 614,310 shs
• Average Volume: 506,337 shs
• Market Capitalization: $112.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lixte Biotechnology Stock Analysis - MarketRank™

Lixte Biotechnology scored higher than 1% of companies evaluated by MarketBeat, and ranked 910th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Lixte Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lixte Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lixte Biotechnology is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lixte Biotechnology is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lixte Biotechnology has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.22% of the float of Lixte Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Lixte Biotechnology has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lixte Biotechnology has recently increased by 83.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lixte Biotechnology does not currently pay a dividend.

Dividend Growth

Lixte Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Lixte Biotechnology this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.50% of the stock of Lixte Biotechnology is held by insiders.

Percentage Held by Institutions

5.10% of the stock of Lixte Biotechnology is held by institutions.

Company Calendar

• Last Earnings: 11/12/2025
• Today: 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LIXT
• CIK: 1335105
• Web: www.lixte.com
• Phone: (631) 830-7092
• Fax: 631-982-5050
• Employees: 4
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -134.91%
• Return on Assets: -95.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.78
• Quick Ratio: 2.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 7.15

Miscellaneous

• Outstanding Shares: 15,020,000
• Free Float: 13,593,000
• Market Cap: $112.80 million
• Optionable: Not Optionable
• Beta: 1.24